SAGE Therapeutics (SAGE) Misses Q2 EPS by 21c
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.88), $0.21 worse than the analyst estimate of ($1.67).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.
SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($1.88), $0.21 worse than the analyst estimate of ($1.67).
For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.